EGFR and non-small cell lung carcinoma: Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received gefitinib or erlotinib (38.6 vs 31.8 months) (Ramalingam et al., 2020).